217 related articles for article (PubMed ID: 12734321)
1. Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
Du XL
J Natl Cancer Inst; 2003 May; 95(9):683; author reply 684-5. PubMed ID: 12734321
[No Abstract] [Full Text] [Related]
2. Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
Jordan VC; Morrow M
J Natl Cancer Inst; 2003 May; 95(9):683-4; author reply 684-5. PubMed ID: 12734320
[No Abstract] [Full Text] [Related]
3. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
Mariotto A; Feuer EJ; Harlan LC; Wun LM; Johnson KA; Abrams J
J Natl Cancer Inst; 2002 Nov; 94(21):1626-34. PubMed ID: 12419789
[TBL] [Abstract][Full Text] [Related]
4. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
5. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
Di Leo A; Buyse M
J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
[No Abstract] [Full Text] [Related]
6. Meeting highlights: International consensus panel on the treatment of primary breast cancer.
Love RR
J Clin Oncol; 2002 Apr; 20(7):1955-6; author reply 1956-7. PubMed ID: 11919263
[No Abstract] [Full Text] [Related]
7. Adjuvant therapy for all patients with breast cancer?
Lippman ME; Hayes DF
J Natl Cancer Inst; 2001 Jan; 93(2):80-2. PubMed ID: 11208870
[No Abstract] [Full Text] [Related]
8. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
9. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
Gamucci T
Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201
[No Abstract] [Full Text] [Related]
10. [National Conference of Medical Oncology. Controversies in the treatment of breast cancer. Genova, October 28, 2000].
Longo F
Tumori; 2000; 86(6):A13-8. PubMed ID: 11271674
[No Abstract] [Full Text] [Related]
11. [The ATAC study on adjuvants in breast cancer].
Bravi S
Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
[No Abstract] [Full Text] [Related]
12. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
[TBL] [Abstract][Full Text] [Related]
13. [Tamoxifen--"golden standard" in the treatment of patients with early breast cancer].
Semiglazov VF; Kostetskaia TV
Vopr Onkol; 2001; 47(1):108-12. PubMed ID: 11317528
[No Abstract] [Full Text] [Related]
14. [Antiestrogenic agents for treatment of advanced breast cancers].
Kimura M
Nihon Rinsho; 2000 Apr; 58 Suppl():311-6. PubMed ID: 11026011
[No Abstract] [Full Text] [Related]
15. [Adjuvant therapy in breast cancer].
Semiglazov VF
Vopr Onkol; 2000; 46(1):18-27. PubMed ID: 10789218
[No Abstract] [Full Text] [Related]
16. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
[TBL] [Abstract][Full Text] [Related]
17. Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer.
Wolff AC; Davidson NE
J Clin Oncol; 2006 Nov; 24(31):4949-51. PubMed ID: 17075110
[No Abstract] [Full Text] [Related]
18. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
Bertelsen L; Bernstein L; Olsen JH; Mellemkjaer L; Haile RW; Lynch CF; Malone KE; Anton-Culver H; Christensen J; Langholz B; Thomas DC; Begg CB; Capanu M; Ejlertsen B; Stovall M; Boice JD; Shore RE; ; Bernstein JL
J Natl Cancer Inst; 2008 Jan; 100(1):32-40. PubMed ID: 18159070
[TBL] [Abstract][Full Text] [Related]
19. Trial data lacking for elderly patients with breast cancer.
Nelson NJ
J Natl Cancer Inst; 2000 Dec; 92(24):1968-9. PubMed ID: 11121451
[No Abstract] [Full Text] [Related]
20. [Current issues in adjuvant hormone therapy of breast cancer].
Semiglazov VF; Semiglazov VV
Vopr Onkol; 2003; 49(6):771-5. PubMed ID: 14976929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
